Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GERON CORPGERN · Entity 4989 | Director | January 13, 2023 | January 18, 2023 |
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | Director | September 16, 2022 | September 21, 2022 |
| Personalis, Inc.PSNL · Entity 4572 | Director | May 12, 2026 | June 11, 2026 |
| VERACYTE, INC.VCYT · Entity 2018 | Director | June 18, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GERON CORP
Report date January 13, 2023 · Filed January 18, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 109,047 |
Reported balance
After 2023-01-13 transaction · row 1
1 source rowRow 1 · 2023-01-13 · Exercise / conversion · Acquired 35,000 · Balance 109,047 |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2023-05-22 | Direct | 0 |
Reported balance
After 2023-01-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-13 · Exercise / conversion · Disposed 35,000 · Balance 0 F1: The options were fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were fully vested.
NEKTAR THERAPEUTICS
Report date September 16, 2022 · Filed September 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,233 |
Reported balance
After 2022-09-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-09-16 · Grant · Acquired 10,200 · Balance 23,233 F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2: This RSU award vests in full, one year following September 16, 2022. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.47 · Expires 2030-09-15 | Direct | 20,400 |
Reported balance
After 2022-09-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-09-16 · Grant · Acquired 20,400 · Balance 20,400 F3: This stock option vests in equal monthly installments over the one-year period beginning on September 16, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
F2: This RSU award vests in full, one year following September 16, 2022.
F3: This stock option vests in equal monthly installments over the one-year period beginning on September 16, 2022.
Personalis, Inc.
Report date May 12, 2026 · Filed June 11, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,756 |
Reported balance
After 2026-05-12 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-05-12 · Grant · Acquired 6,250 · Balance 19,756 F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan (the "2019 Plan")) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such Change in Control. F2: This amendment corrects the number of shares of Common Stock reported as beneficially owned by the Reporting Person on the Form 4 filed on May 14, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders occurring after the grant date, subject to the reporting person's Continuous Service (as defined in the Company's 2019 Equity Incentive Plan (the "2019 Plan")) through the vesting date. In the event of a Change in Control (as defined in the 2019 Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such Change in Control.
F2: This amendment corrects the number of shares of Common Stock reported as beneficially owned by the Reporting Person on the Form 4 filed on May 14, 2026.
VERACYTE, INC.
Report date June 18, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,097 |
Ending reported balance
After 2026-06-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-18 · Sale · Disposed 3,200 · Balance 15,626 F1: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 5, 2025. F2: Represents weighted average sales price. Sale prices for the transactions range from $52.26 to $53.26. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Row 2 · 2026-06-18 · Sale · Disposed 529 · Balance 15,097 F1: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 5, 2025. F3: Represents weighted average sales price. Sale prices for the transactions range from $53.29 to $53.70. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 5, 2025.
F2: Represents weighted average sales price. Sale prices for the transactions range from $52.26 to $53.26. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
F3: Represents weighted average sales price. Sale prices for the transactions range from $53.29 to $53.70. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ILLUMINA, INC.
Report date January 22, 2014 · Filed May 29, 2019
Section 16 reporting ended · disclosed 2019-05-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,249 |
Reported balance
After 2014-01-22 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2014-01-22 · Gift · Disposed 200 · Balance 10,249 |
| Common StockSEC Table I · non-derivative | Direct | 10,049 |
Reported balance
After 2019-05-23 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2019-05-23 · Tax withholding · Disposed 589 · Balance 10,049 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2022 Filed May 11, 2022 22:15 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001062993-22-012153 · form4.xml · derivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-05-09 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| April 20, 2022 Filed Apr 22, 2022 00:09 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001062993-22-010624 · form4.xml · derivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2022-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Option was fully vested. F1 · derivative.exercise_date: Option was fully vested. Read SEC document |
| April 20, 2022 Filed Apr 22, 2022 00:09 UTC | GERON CORP GERN · Entity 4989 | Exercise / conversionCommon Stock | 35,000 | $1.41 | $49,350.00 |
DisclosureSEC source: 0001062993-22-010624 · form4.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 21:44 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $12.12 | $0.00 |
DisclosureSEC source: 0001384101-21-000184 · wf-form4_164003664535663.xml · derivative · entry 3 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,750 Underlying: Common Stock · 5,000 shares Expires 2023-10-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 17, 2021. F2 · derivative.exercise_date: The option is fully vested. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 21:44 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 5,000 | $45.00 | $225,000.00 |
DisclosureSEC source: 0001384101-21-000184 · wf-form4_164003664535663.xml · nonDerivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,720 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 17, 2021. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 21:44 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 5,000 | $12.12 | $60,600.00 |
DisclosureSEC source: 0001384101-21-000184 · wf-form4_164003664535663.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 17, 2021. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:19 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 1,241 | $49.48 | $61,409.40 |
DisclosureSEC source: 0001384101-21-000163 · wf-form4_163597436143646.xml · nonDerivative · entry 3 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 0 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 25, 2020. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $49.35 to $49.53. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:19 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 2,959 | $49,015.00 | $145,035,385.00 |
DisclosureSEC source: 0001384101-21-000163 · wf-form4_163597436143646.xml · nonDerivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 1,241 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 25, 2020. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $48.30 to $49.29. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 21:19 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 200 | $47.73 | $9,545.00 |
DisclosureSEC source: 0001384101-21-000163 · wf-form4_163597436143646.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 4,200 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 25, 2020. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $47.25 to $47.89. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 22:15 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 20,400 | $0.00 Strike: $17.78 | $0.00 |
DisclosureSEC source: 0001209191-21-057706 · doc4.xml · derivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,400 Underlying: Common Stock · 20,400 shares Expires 2029-09-21 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 22, 2021. Read SEC document |
| September 22, 2021 Filed Sep 24, 2021 22:15 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 10,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-057706 · doc4.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,300 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. F2 · deemedExecutionDate: This RSU award vests in full, one year following September 22, 2021. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:19 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 1,554 | $44.57 | $69,267.69 |
DisclosureSEC source: 0001384101-21-000146 · wf-form4_162810834688133.xml · nonDerivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 4,400 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 25, 2020. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $44.07 to $44.81. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 20:19 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 2,846 | $43.54 | $123,926.22 |
DisclosureSEC source: 0001384101-21-000146 · wf-form4_162810834688133.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 5,954 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 25, 2020. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $43.03 to $44.00. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 20:11 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 8,720 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-21-000109 · wf-form4_162335584509410.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,720 F1 · kind: Restricted stock units awarded on June 8, 2021 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer. Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:27 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantStock Option (right to buy) · Derivative | 4,229 | $0.00 Strike: $19.74 | $0.00 |
DisclosureSEC source: 0001209191-21-033496 · doc4.xml · derivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,229 Underlying: Common Stock · 4,229 shares Expires 2031-05-14 F2 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders. In the event of a change in control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the option shall vest and become immediately exercisable prior to the effectiveness of such change in control. Read SEC document |
| May 14, 2021 Filed May 18, 2021 20:27 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantCommon Stock | 2,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-033496 · doc4.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,736 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 100% of the shares subject to the RSU shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders. In the event of a change in control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the RSU shall vest immediately prior to the effectiveness of such change in control. Read SEC document |
| May 11, 2021 Filed May 14, 2021 01:22 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 83,000 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0000886744-21-000038 · edgar.xml · derivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 Underlying: Common Stock · 83,000 shares Expires 2031-05-10 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:41 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 250 | $50.03 | $12,507.00 |
DisclosureSEC source: 0001384101-21-000074 · wf-form4_162024723253740.xml · nonDerivative · entry 3 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 8,800 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 25, 2020. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $49.92 to $50.10. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:41 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 650 | $49.00 | $31,849.03 |
DisclosureSEC source: 0001384101-21-000074 · wf-form4_162024723253740.xml · nonDerivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 9,050 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 25, 2020. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $48.55 to $49.22. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:41 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 3,527 | $48.01 | $169,343.61 |
DisclosureSEC source: 0001384101-21-000074 · wf-form4_162024723253740.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By IRA Disclosed balance after: 9,700 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 25, 2020. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $47.54 to $48.40. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:45 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 6,250 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001384101-21-000022 · wf-form4_161437592691639.xml · derivative · entry 5 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires 2022-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 12, 2020. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:45 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 200 | $61.77 | $12,354.00 |
DisclosureSEC source: 0001384101-21-000022 · wf-form4_161437592691639.xml · nonDerivative · entry 4 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 12, 2020. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:45 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 3,606 | $61.09 | $220,298.83 |
DisclosureSEC source: 0001384101-21-000022 · wf-form4_161437592691639.xml · nonDerivative · entry 3 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 12, 2020. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $60.62 to $61.59. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:45 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 2,444 | $60.03 | $146,705.74 |
DisclosureSEC source: 0001384101-21-000022 · wf-form4_161437592691639.xml · nonDerivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,806 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 12, 2020. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $59.57 to $60.52. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 21:45 UTC | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 6,250 | $4.00 | $25,000.00 |
DisclosureSEC source: 0001384101-21-000022 · wf-form4_161437592691639.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 12, 2020. Read SEC document |
| February 25, 2021 Filed May 5, 2021 20:34 UTC Amendment | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionStock Option (right to buy) · Derivative | 6,250 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001384101-21-000072 · wf-form4a_162024685939960.xml · derivative · entry 6 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires 2022-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 12, 2020. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| February 25, 2021 Filed May 5, 2021 20:34 UTC Amendment | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 200 | $61.77 | $12,354.00 |
DisclosureSEC source: 0001384101-21-000072 · wf-form4a_162024685939960.xml · nonDerivative · entry 4 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 12, 2020. Read SEC document |
| February 25, 2021 Filed May 5, 2021 20:34 UTC Amendment | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 3,606 | $61.09 | $220,298.83 |
DisclosureSEC source: 0001384101-21-000072 · wf-form4a_162024685939960.xml · nonDerivative · entry 3 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 12, 2020. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $60.62 to $61.59. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| February 25, 2021 Filed May 5, 2021 20:34 UTC Amendment | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 2,444 | $60.03 | $146,705.74 |
DisclosureSEC source: 0001384101-21-000072 · wf-form4a_162024685939960.xml · nonDerivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,806 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 12, 2020. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $59.57 to $60.52. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| February 25, 2021 Filed May 5, 2021 20:34 UTC Amendment | VERACYTE, INC. VCYT · Entity 2018 | Exercise / conversionCommon Stock | 6,250 | $4.00 | $25,000.00 |
DisclosureSEC source: 0001384101-21-000072 · wf-form4a_162024685939960.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 12, 2020. Read SEC document |
| September 22, 2020 Filed Sep 25, 2020 01:38 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 18,200 | $0.00 Strike: $18.91 | $0.00 |
DisclosureSEC source: 0001209191-20-052042 · doc4.xml · derivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,200 Underlying: Common Stock · 18,200 shares Expires 2028-09-21 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 22, 2020. Read SEC document |
| September 22, 2020 Filed Sep 25, 2020 01:38 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 9,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052042 · doc4.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,100 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 22, 2020. Read SEC document |
| September 22, 2020 Filed Sep 26, 2020 00:13 UTC Amendment | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 18,200 | $0.00 Strike: $19.90 | $0.00 |
DisclosureSEC source: 0001209191-20-052154 · doc4a.xml · derivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,200 Underlying: Common Stock · 18,200 shares Expires 2028-09-21 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 22, 2020. Read SEC document |
| September 22, 2020 Filed Sep 26, 2020 00:13 UTC Amendment | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 9,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052154 · doc4a.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,100 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 22, 2020. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:47 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $26.30 | $0.00 |
DisclosureSEC source: 0001384101-20-000095 · wf-form4_159173563548456.xml · derivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-07 F1 · derivative.exercise_date: The option becomes exercisable in full on June 8, 2021 or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the option vests in full in the event of a change in control of the Company. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 22:11 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 83,000 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0000886744-20-000048 · edgar.xml · derivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 Underlying: Common Stock · 83,000 shares Expires 2030-06-04 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| May 15, 2020 Filed May 19, 2020 22:10 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $11.22 | $0.00 |
DisclosureSEC source: 0001209191-20-030651 · doc4.xml · derivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2030-05-14 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the day prior to the Company's next annual meeting of stockholders. In the event of a change in control (as defined in the Company's 2019 Equity Incentive Plan), the shares underlying the option shall vest and become immediately exercisable prior to the effectiveness of such change in control. Read SEC document |
| September 25, 2019 Filed Sep 27, 2019 22:10 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 13,000 | $0.00 Strike: $18.80 | $0.00 |
DisclosureSEC source: 0001209191-19-051043 · doc4.xml · derivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2027-09-24 F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 30, 2019. Read SEC document |
| September 25, 2019 Filed Sep 27, 2019 22:10 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-051043 · doc4.xml · nonDerivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. F2 · deemedExecutionDate: This restricted stock unit award vests in full, one year following September 25, 2019. Read SEC document |
| September 09, 2019 Filed Sep 16, 2019 23:51 UTC | Personalis, Inc. PSNL · Entity 4572 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $15.92 | $0.00 |
DisclosureSEC source: 0001209191-19-049724 · doc4.xml · derivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2029-09-08 F1 · derivative.exercise_date: The shares underlying the option vest in three successive equal annual installments over the three-year period measured from September 9, 2019. Read SEC document |
| June 12, 2019 Filed Jun 13, 2019 20:38 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $27.01 | $0.00 |
DisclosureSEC source: 0001384101-19-000072 · wf-form4_156045830694990.xml · derivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: The option becomes exercisable in full on June 12, 2020 or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the option vests in full in the event of a change in control of the Company. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 23:22 UTC | GERON CORP GERN · Entity 4989 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0000886744-19-000061 · edgar.xml · derivative · entry 1 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-06-05 F1 · derivative.exercise_date: This option will vest and become exercisable as to 100% of the shares of common stock subject to such option on the earlier of (i) the date of the next annual meeting of the Company's stockholders or (ii) the first anniversary of the date of grant of such option, subject to the non-employee director's continuous service with the Company through such dates. Read SEC document |
| May 23, 2019 Filed May 29, 2019 01:01 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 589 | $308.97 | $181,983.33 |
DisclosureSEC source: 0001127602-19-020073 · form4.xml · nonDerivative · entry 2 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,049 Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 22:03 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionNon-qualified Stock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $71.09 | $0.00 |
DisclosureSEC source: 0001127602-19-001359 · form4.xml · derivative · entry 18 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600 Underlying: Common Stock · 4,000 shares Expires 2023-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 22:03 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 100 | $296.78 | $29,677.56 |
DisclosureSEC source: 0001127602-19-001359 · form4.xml · nonDerivative · entry 17 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,838 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F13 · price: Weighted average sale price representing 100 shares sold ranging from $296.64 to $297.00 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 22:03 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 117 | $295.93 | $34,623.92 |
DisclosureSEC source: 0001127602-19-001359 · form4.xml · nonDerivative · entry 16 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,938 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F12 · price: Weighted average sale price representing 117 shares sold ranging from $295.56 to $296.18 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 22:03 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 232 | $294.73 | $68,377.94 |
DisclosureSEC source: 0001127602-19-001359 · form4.xml · nonDerivative · entry 15 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,055 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F11 · price: Weighted average sale price representing 232 shares sold ranging from $294.20 to $295.08 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 22:03 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 350 | $293.59 | $102,754.75 |
DisclosureSEC source: 0001127602-19-001359 · form4.xml · nonDerivative · entry 14 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,287 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F10 · price: Weighted average sale price representing 350 shares sold ranging from $293.02 to $294.01 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 22:03 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 134 | $292.27 | $39,163.55 |
DisclosureSEC source: 0001127602-19-001359 · form4.xml · nonDerivative · entry 13 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,637 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F9 · price: Weighted average sale price representing 134 shares sold ranging from $292.02 to $292.77 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 22:03 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 67 | $291.02 | $19,498.28 |
DisclosureSEC source: 0001127602-19-001359 · form4.xml · nonDerivative · entry 12 EASTHAM KARIN · CIK 0001231845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,771 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F8 · price: Weighted average sale price representing 67 shares sold ranging from $290.63 to $291.42 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request.\ Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.